US20040058994A1 - Local prevention or amelioration of pain from surgically closed wounds - Google Patents

Local prevention or amelioration of pain from surgically closed wounds Download PDF

Info

Publication number
US20040058994A1
US20040058994A1 US10/669,365 US66936503A US2004058994A1 US 20040058994 A1 US20040058994 A1 US 20040058994A1 US 66936503 A US66936503 A US 66936503A US 2004058994 A1 US2004058994 A1 US 2004058994A1
Authority
US
United States
Prior art keywords
method
patch
percent
anesthetic
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/669,365
Inventor
R. Cassel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Pharmaceuticals Inc
Original Assignee
Immune Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/425,925 priority Critical patent/US6383511B1/en
Priority to US10/137,685 priority patent/US6645521B2/en
Application filed by Immune Pharmaceuticals Inc filed Critical Immune Pharmaceuticals Inc
Priority to US10/669,365 priority patent/US20040058994A1/en
Publication of US20040058994A1 publication Critical patent/US20040058994A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402Anaestetics, analgesics, e.g. lidocaine

Abstract

A non-invasive and non-systemic method for intradermal prevention OR amelioration of pain from a surgically closed wound is disclosed. The method comprises topical delivery of a local anesthetic to an exterior surface of a surgically closed wound.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a local method to prevent or ameliorate the pain associated with surgical incision by topically administering a local anesthetic. [0001]
  • BACKGROUND OF THE INVENTION
  • The skin is a complex multilayer organ with a total thickness of 2-3 mm. The panniculus adiposus, a variably thick fatty layer, is below the dermis. The dermis is a layer of dense connective tissue that supports the epidermis. The epidermis comprises a layer of epithelial cells and is about 100 μm thick. The epidermis is further classified into a number of layers, of which the outermost layer is the stratum corneum (15-20 μm thick). The stratum corneum comprises highly dense, keratinized tissue and is the skin's main source of penetration and permeation resistance (Montagna, W. and Parakkal, P. F. (1974) [0002] The Structure and Function of Skin, Academic Press, New York and Holbrook, K. A. and Wolf, K. (1993) The Structure and Development of Skin, In: Dermatology in General Medicine, Vol 1, 4th ed., Eds. T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. Feedberg, and K. F. Austen, McGraw Hill, Inc., New York, pp. 97-145).
  • Because of the skin's drug permeation resistance, as little as about 1 percent and usually no more than about 15 percent of a drug in a dermatological formulation is bioavailable (Ghosh, T. K.; Pfister, W. R.; Yum, S. I. [0003] Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc. p. 7).
  • After a surgical procedure, pain results from pain receptor stimulation. Postoperative or post-traumatic pain is caused by stimulation of sub-dermal sensory nerve receptors (i.e., nociceptors). And trauma is increased over the first 24-48 hours by phases of reactive edema and by release of cytokines and chemo reactive agents. [0004]
  • After a wound is closed by a surgical professional, pain prevention options are limited, especially outpatient pain control and management. Traditionally, for post wound closure pain prevention, opiates and NSAIDs are administered systemically, i.e., throughout the organism via the circulatory system. Topical intradermal pain prevention has seen little application, likely because surgically closed wounds are expected to present a drug permeation barrier similar to intact skin. [0005]
  • Systemic administration of pain relief drugs usually is effected orally or intravenously. The AHCPR Guidelines suggested pain control options include: systemic administration of non-steroidal anti-inflammatory drugs (NSAIDs) or opiates using the traditional “as needed” schedule or around-the-clock administration (American Pain Society, 1989). [0006]
  • Systemic pharmacotherapies are, however, accompanied by adverse side effects, particularly with continuous use. With NSAIDs, there is a high risk of gastric disorders, erosions of the stomach lining and the intestinal mucus membrane and bleeding. Administration of opiates and narcotics presents a high dependency risk aside from other undesirable effects, like, respiratory depression, sedation, dizziness, nausea, and constipation. Furthermore, systemic use of these substances while taking other medications can result in detrimental pharmacologic interactions. Of course, pharmacological interactions become more significant in an ambulatory postoperative patient for whom polypharmacy is necessary. [0007]
  • In contrast to prevention of pain with systemic agents, pain can also be treated locally, that is, by delivering the pain reliever directly to the painful area. Thus, for example, a local anesthetic or NSAID might be injected at the pain area. [0008]
  • Local anesthetics reversibly block impulse conduction along nerve axons and other excitable membranes that utilize sodium channels as the primary means of action potential generation. This blocking action can be used clinically to block pain sensation at specific areas of the body (Strichartz, G. R. (Ed.) Local Anesthetics, Handbook of Experimental Pharmacology, Vol. 81, Springer, Berlin/New York, 1987). Furthermore, local anesthetics generally possess a good tissue tolerance, and in some cases, local anesthetics have bactericidal properties, and may impart a positive influence on the regional vessel innervation during wound healing and episodes of. [0009]
  • Traditionally, pain relief with local anesthetics—at least for the more painful wounds, such as surgically closed wounds—involves injection into the area of the nerve fibers to be blocked (Jones M. Gregg A K, Anaesthesia February 1999;54(2):200). But with this therapy, the medical professional is confronted with the risk/benefit consideration between the negative effects of systemic absorption versus achieving pain relieving concentrations at the pain site. Systemic absorption of injected local anesthetics is modified by several factors, including dosage, injection site, drug tissue binding. For example, local anesthetic injection to a highly vascular area results in more rapid systemic absorption and thus, adversely, higher drug blood levels are attained. In an analogy to injection, local anesthetics have also been infused directly into open wounds before surgical closure (e.g., U.S. Pat. Nos. 5,272,139 and 5,922,340). [0010]
  • In addition to systemic absorption risk, local injection is painful and invasive and also requires professional administration. Of course, with surgically closed wounds, which are very sensitive, injections should be avoided if possible. [0011]
  • While topical application of local anesthetics might overcome some of the problems associated with injection (especially systemic dangers), this method has not been widely used, mainly, as discussed above, by the difficulty to get significant concentrations through skin barrier. Further advantages of topical administration include improved patient compliance and reversible action (i.e., the action can be reversed by removing the anesthetic from the application site) (Ghosh, T. K.; Pfister, W. R.; Yum, S. I. [0012] Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc. pp. 33-112).
  • Thus, topical administration of local anesthetics has, in general, only been used to treat minor pain where small concentrations of the anesthetic will suffice. For example, for relief of minor pain from scrapes, skin irritations. Topical administration of local anesthetics is also indicated for topical anesthesia prior to needle insertion (e.g., blood sampling, vaccination, allergy testing), and superficial surgical procedures (Zook et al. U.S. Pat. No. 5,415,866; Royds, R. B. U.S. Pat. No. 5,466,465; Zhange et al. U.S. Pat. No. 5,919,479; and Berkovitch, et al. [0013] J. Clin. Pharmacol. 35: 295-297).
  • In addition to classic local anesthetics—i.e., amide and ester type—several of the more potent NSAIDs have been developed into topical products for local application to minor pain sites—for example, Cordran® Tape delivers flurandrenolide for relief of inflammatory and puritic conditions (Oclassen (1995) Cordon Tape Package Insert, Oclassen Pharmaceutical, San Rafael, Calif.). [0014]
  • But, in brief, topical application of local anesthetics is not known to treat the more intense pain associated with wounds after surgical closure. This is likely because a surgically closed wound is expected to present the same permeability difficulties associated with intact skin. [0015]
  • Surgically closed wounds are tightly welded. The most common techniques for closure of open wounds is suturing (with either non-absorbable and absorbable materials) and stapling. These mechanical closure methods provide tension on the skin tissue at the wound border that encourages epithelial tissue to migrate toward the wound and cover it. As the skin heals, the wound becomes even more impenetrable by pharmaceuticals, nonetheless, the pain persists. Also, modern surgical suturing techniques and intraoperative hemostasis, wound treatment has been greatly advanced by the use of suitable supplementary materials, such as tissue glues and adhesives, to accelerate hemostasis as well as to optimize conditions and control of wound closure. Fibrin-based biological glues have proven particularly advantageous over non-biological adhesives because fibrin-based glues mimic the natural coagulation cascade and enhance the healing process. [0016]
  • In short, surgically closed wounds are expected to present a formidable barrier against penetration of topically applied pain relief agents in sufficient concentration to relived the intense pain once the original anesthetic (systemic or locally injected) used in the surgery has worn off. [0017]
  • Thus far a non-invasive and non-systemic treatment for pain resulting from surgically closed wounds—e.g., closed wounds, wherein the wound resulted from a surgical procedure, such as laporasopy or any non-surgical occurrence, such as, accidental knife cuts, etc.—has not been available. [0018]
  • SUMMARY OF THE INVENTION
  • The present invention concerns a non-invasive and non-systemic method for prevention or amelioration of incisional pain resulting from a surgically closed wound. The inventors have found that topically applied local anesthetics can be used to treat the pain associated with a surgically closed wound. [0019]
  • In one embodiment the invention comprises, a method of preventing pain from a surgically closed wound in a subject comprising applying a pharmaceutically acceptable topical drug formulation comprising a therapeutically effective dose of a local anesthetic or a pharmaceutically acceptable salt thereof on or adjacent to an exterior surface of the wound. The wound can be any wound such as an accidental knife cut, preferably the wound resulted from a surgical procedure. [0020]
  • In a preferred embodiment the method of the invention may be used to prevent the pain from surgically closed wounds resulting from laparoscopy, hemiaplasty, breast biopsy, or excision of subcutaneous tumors. [0021]
  • Any local anesthetic can be used with the current invention. Preferred local aesthetics include lidocaine, tetracaine, bupivacaine, prilocaine, mepivacaine, procaine, chloroprocaine, ropivacaine, dibucaine, etidocaine, or benzocaine or any mixtures thereof. The most preferred local anesthetic is lidocaine. [0022]
  • In another embodiment, the current invention concerns a patch comprising a local anesthetic in an amount therapeutically effective to prevent or ameliorate pain from a surgically closed wound in a mammal suffering from the pain packaged in association with instructions, the instructions comprising: applying the patch to the surgically closed wound such that the patch covers at least a part of the area of the surgically closed wound. [0023]
  • These and other features, aspects, and advantages of the invention will become better understood with reference to the following detailed description, example, and appended claims. [0024]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention may be used to prevent or ameliorate pain from any surgically closed wound by topically applying a local anesthetic in a pharmaceutically acceptable topical drug formulation. The pharmaceutically acceptable topical drug formulation may be contained in a patch. [0025]
  • According to the invention the term “subject” means any mammal, including domesticated mammals, like dogs and cats. Preferably, the subject is a human. [0026]
  • As used herein, the term “local anesthetic” means any drug that provides local numbness or analgesia or any drug that provides a regional blockage of nociceptive pathways (afferent and/or efferent). The meaning of “local anesthetic” also encompasses drugs not traditionally associated with local anesthetic properties but which have a local anesthetic effect, like NSAIDs (e.g., acetylsalicylic acid, ketoprofen, piroxicam, diclofenac, indomethacin, ketorolac, Vioxx®, and Celebrex®), opioids as described in U.S. Pat. No. 5,589,480 (e.g., morphine or morphine sulfate), and other agents. [0027]
  • The local anesthetic can be any local anesthetic known or to be developed. The amide and ester type local anesthetics are preferred. Amide type local anesthetics are characterized by an amide functionality, while ester type local anesthetics contain an ester functionality. Preferred amide type local anesthetics are: lidocaine, bupivacaine, prilocaine, mepivacaine, etidocaine, ropivacaine, dibucaine, and mixtures thereof. Preferred ester type local anesthetics are: tetracaine, procaine, benzocaine, chloroprocaine, and any mixture thereof. The most preferred local anesthetic is lidocaine. [0028]
  • When the local aesthetic contains a basic functionality, it may be present in the form of an acid addition salt or as the free base. Preferred salts are the hydrochloride, bromide, acetate, citrate, carbonate or sulfate salts. But preferably, the local anesthetic agent is in the form of a free base. More preferably lidocaine is used in the free base form. [0029]
  • Furthermore, in order to improve the effectiveness and tolerance of the present topically effective therapy, local anesthetics with different pharmacodynamics and pharmacokinetics may be combined in a pharmaceutically acceptable topical drug formulation. A preferred combination of local anesthetics is lidocaine and prilocaine and another preferred combination is lidocaine and tetracaine. [0030]
  • The term “surgically closed wound”, as used herein, means any wound that has been closed, such that, the opposing edges of skin—which comprise the wound—have been joined together by a device or material. Preferably, the wound has been closed by a medical professional, such as, a surgeon, doctor, doctors assistant, emergency medical technician, or nurse. [0031]
  • Surgically closed wounds include but are not limited to wounds that have been closed with: sutures (absorbable or non-absorbable, synthetic or natural), staples, and biological glues. [0032]
  • The term “topical drug formulation” means a formulation designed for topical skin application and containing a drug, for example, a formulation in the form of a polymer matrix, cream, gel, emulsion, or ointment. [0033]
  • Application is accomplished by applying the topical drug formulation on or adjacent to an exterior surface of the surgically closed wound. Preferably the topical drug formulation is applied directly to the surface of the surgically closed wound. The pharmaceutically acceptable topical drug formulation of the invention should be applied using a sterile technique. [0034]
  • The term “drug” means a substance used in the diagnosis, treatment, or prevention of a disease or medical condition or an active component of a medication. Of course, the term “drug” encompasses local anesthetics. [0035]
  • As used herein “patch” comprises at least a topical drug formulation and a covering layer, such that, the patch can be placed over the surgically closed wound thereby positioning the patch/drug formulation adjacent to the wound's surface. Preferably the patch is designed to maximize drug delivery through the stratum comeum, upper epidermis, and into the dermis, and to minimize absorption into the circulatory system, reduce lag time, promote uniform absorption, and reduce mechanical rub-off. [0036]
  • The topical drug formulations and patch systems according to the invention preferably provide controlled release of a local anesthetic agent to the surgically closed wound. [0037]
  • In one embodiment of the invention, the topical drug formulation comprises a carrier system. Pharmaceutically effective carriers include buffered solutions, e.g, hypotonic or buffered saline, liposomes and the like or any other art-known pharmaceutically acceptable topical carrier. More preferred carriers include creams, ointments, oils, plasters, and emulsions. A more complete listing of art-known carriers is provided by reference texts that are standard in the art, for example, [0038] Remington's Pharmaceutical Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published by Mack Publishing Company, Easton, Pa., the disclosures of which are incorporated by reference herein in their entireties.
  • After application of the topical drug formulation to the surgically closed wound, the wound may be covered with a dressing. The term “dressing”, as used herein, means a covering designed to protect a previously applied drug formulation. “Dressing” includes coverings such as a bandage, which may be porous or non-porous and various inert covenngs, e.g., a plastic film wrap or other non-absorbent film. The term “dressing” also encompasses non-woven or woven coverings, particularly elastomeric coverings, which allow for heat and vapor transport. These dressings allow for cooling of the pain site, which provides for greater comfort. [0039]
  • In a preferred embodiment of the current invention, the topical drug formulation containing a local aesthetic is contained in a patch that is applied adjacent to the surface of the surgically closed wound. Preferably, the patch components resemble the viscoelastic properties of the skin and conform to the skin during movement to prevent undue shear and delamination. [0040]
  • A patch containing a topical drug formulation has advantages over the simple topical drug formulation alone. One advantage is that the dose is controlled by the patch's surface area. Other advantages of patches are constant rate of delivery, longer duration of action (the ability of to adhere to the skin for 1, 3, 7 days or longer); improved patient compliance, non-invasive dosing, and reversible action (i.e., the patch can simply be removed). [0041]
  • A patch suitable for use with the invention should contain at least: (1) a backing layer and (2) a carrier formulated with a local anesthetic. [0042]
  • Preferred patches include (1) the matrix type patch; (2) the reservoir type patch; (3) the multi-laminate drug-in-adhesive type patch; and (4) the monolithic drug-in-adhesive type patch; and (Ghosh, T. K.; Pfister, W. R.; Yum, S. I. [0043] Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc. p. 249-297, incorporated herein by reference). These patches are well known in the art and generally available commercially.
  • For practice of the invention, the matrix type and the drug-in-adhesive type patches are especially preferred. The more preferred drug-in-adhesive patch is the monolithic type. [0044]
  • The matrix patch comprises an anesthetic containing matrix, an adhesive backing film overlay, and preferably, a release liner. In some cases, it may be necessary to include a impermeable layer to minimize drug migration into the backing film (e.g., U.S. Pat. No. 4,336,243, incorporated herein by reference). The anesthetic containing matrix is held against the skin by the adhesive overlay. Examples of suitable anesthetic matrix materials include but are not limited to lipophilic polymers, such as polyvinyl chloride, polydimethylsiloxane, and hydrophilic polymers like polyvinylpyrrolidone, polyvinyl alcohol, hydrogels based on gelatin, or polyvinylpyrrolidone/polyethylene oxide mixtures. [0045]
  • The reservoir type patch design is characterized by a backing film coated with an adhesive, and a reservoir compartment containing a drug formulation preferably, in the form of a solution or suspension, that is separated from the skin by a semipermeable membrane (e.g., U.S. Pat. No. 4,615,699, incorporated herein by reference). The adhesive coated backing layer extends around the reservoir's boundaries to provide a concentric seal with the skin and hold the reservoir adjacent to the wound. [0046]
  • The monolithic drug-in-adhesive patch design is characterized by the inclusion of the drug formulation in the skin contacting adhesive layer, a backing film and preferably, a release liner. The adhesive functions both to release the anesthetic and adhere the anesthetic matrix to the skin. The drug-in-adhesive system does not require an adhesive overlay and thus the patch size is minimized. Also, drug-in-adhesive type patches are thin and comfortable (e.g., U.S. Pat. No. 4,751,087, incorporated herein by reference). [0047]
  • The multi-laminate drug-in-adhesive patch design further incorporates additional semi-permeable membrane between two distinct drug-in-adhesive layers or multiple drug-in-adhesive layers under a single backing film (Peterson, T. A. and Dreyer, S. J. Proceed. [0048] Intern. Symp. Control. Rel. Bioact. Mater. 21: 477-478, incorporated herein by reference).
  • Semi permeable membranes, useful with the reservoir or multi-laminate patch, include thin non-porous ethylene vinyl acetate films or thin microporous films of polyethylene employed in microlaminate solid state reservoir patches. [0049]
  • Adhesives for use with the drug-in-adhesive type patches are well known in the art and selection is readily accomplished by an ordinary practitioner. Three basic types commonly used are polyisobutylenes, silicones, and acrylics. Adhesives useful in the present invention can function under a wide range of conditions, such as, high and low humidity, bathing, sweating etc. Preferably the adhesive is a composition based on natural or synthetic rubber, polyacrylate, polyvinylacetate, polybutylacrylate, polymethylacrylate, polydimethylsiloxane, and hydrogels (e.g., high molecular weight polyvinylpyrrolidone and oligomeric polyethylene oxide). The most preferred is polyacrylate. [0050]
  • Suitable release liners include but are not limited to occlusive, opaque, or clear polyester films with a thin coating of pressure sensitive release liner (e.g., silicone-fluorsilicone, and perfluorcarbon based polymers. [0051]
  • Backing films may be occlusive or permeable and are derived from synthetic polymers like polyolefin oils polyester, polyethylene, polyvinylidine chloride, and polyurethane or from natural materials like cotton, wool, etc. Occlusive backing films, such as synthetic polyesters, result in hydration of the outer layers of the stratum corneum while non-occlusive backings allow the area to breath (i.e., promote water vapor transmission from the skin surface). More preferably the backing films are occlusive and comprised of a polyolefin oil. [0052]
  • Additionally, in order to make the present therapy safer, use-specific, and more manageable overall, the present patch may have such a geometric shape such that it corresponds to the special conditions of the application field. Thus, the shape of the patch can be flat or three-dimensional, round, oval, square, and have concave or convex outer shapes, or the patch or bandage can also be segmented by the user into corresponding shapes with or without additional auxiliary means. [0053]
  • Selection of the appropriate dosage for the application site is an important consideration. The rate of intradermal anesthetic delivery from the topical drug formulation or patch is a function of skin permeability, and skin permeability has been shown to vary between anatomical sites depending on the thickness of the stratum comeum. For example, the permeability, in general, increases in order from planter foot arch, lateral ankle, palm, ventral forearm, dorsal forearm, back, chest, thigh, abdomen, scalp, axilla, forehead, and scrotum (Wester, R. C. and Maibach, H. I. (1989) Regional variation in Percutaneous Absorption: In [0054] Percutaneous Absorption, Mechanism, Methodology, Drug Delivery, 2nd ed., Eds. R. L. Bronaugh and H. I. Maibach, Marcel Dekker, Inc., New York, pp. 111-119 (incorporated herein by reference)). Of course, the dosages and dosing frequency will be determined by a trained medical professional, and will depend upon many factors such as wound location, size, severity, and the type of surgical closure.
  • Topical formulations in the form of a gel, cream, or ointment, containing the local anesthetic may be applied adjacent to the surgically closed wound such that the wound and a portion of its surrounding area are covered. The amount of local anesthetic in the topical drug formulation will generally be in the range of about 1 percent to about 25 percent (percents are by weight), preferably, in the range of about 2 percent to about 20 percent, most preferably about 3 percent to about 5 percent. [0055]
  • With gels, creams, or ointments, typically 1 to 4 applications are required per day. Generally, about 0.5 g/cm[0056] 2 to about 5 g/cm2, preferably 1 g/cm2 to about 2 g/cm2 of the topical drug formulation is applied to and around the wound. Preferably a lidocaine topical formulation—wherein the lidocaine concentration is about 1 percent to about 10 percent, more preferably about 2 percent to about 5 percent—is applied to the surgically closed wound in an amount of about 1 g/cm2 to about 2 g/cm2 in the area of and around the wound. After application, preferably, the wound is covered with a dressing.
  • When a combination of local anesthetics is used, the preferred combination is a eutectic mixture of lidocaine and prilocaine. In such a mixture, the amount of lidocaine can range from about 1 percent to about 40 percent, preferably from about 2 percent to about 20 percent, and more preferably from about 3 percent to about 5 percent and the amount of prilocaine can range from about 0.5 percent to about 40 percent, preferably from about 2 percent to about 20 percent, and more preferably about 3 percent to about 5 percent. Preferably the mixture is formulated as an oil in water emulsion. [0057]
  • Another preferred local aesthetic combination is a mixture of lidocaine and tetracaine. In such a mixture, the amount of lidocaine can range from about 1 percent to about 40 percent, preferably from about 2 percent to about 20 percent, and more preferably from about 3 percent to about 5 percent and the amount of tetracaine can range from about 0.5 percent to about 40 percent, preferably from about 2 percent to about 20 percent, and more preferably about 3 percent to about 5 percent. Preferably the mixture is formulated as an oil in water emulsion. [0058]
  • When a patch is used to relieve the pain from a surgically closed wound, the dosage of the local anesthetic required to achieve pain relief is determined by the active surface area of the medicated portion of the patch in direct contact with the skin. Several dosage strengths are advantageous depending upon the severity of the wound. In general, a physician may begin dosing with a low or intermediate strength patch and then, depending upon the effectiveness, adjust the dosage up or down by prescribing a patch of higher or lower anesthetic concentration or a patch of larger or smaller surface area, or, in some cases, multiple patches. [0059]
  • In general, the anesthetic will comprise from about 0.5 percent to about 40 percent by weight of the patch, preferably from about 10 percent to about 30 percent, more preferably from about 15 percent to about 25 percent, and most preferably from about 18 percent to about 22 percent by weight of the patch. Fresh patches may be applied multiple times per day, but, preferably, a fresh patch is applied about every 18 to about every 48 hours. More preferably, the patch is applied daily. [0060]
  • In another embodiment of the current invention, the local anesthetics used in the topical drug formulations and patches are in a form capable of transport into the dermis. Administration of these drug formulations according to the invention may involve the use of excipients. Any pharmaceutically acceptable excipient is suitable. For example, penetration enhancers, plasticisers, antioxidants, colorants, preservatives, antibiotics, etc. [0061]
  • The method of the invention may be used with other conventional systemic pain relief therapies, including but not limited to analgesics, opiates, and narcotics. [0062]
  • When practicing the invention, medicinal agents or their salts may be incorporated into the topical drug formulation or into the appropriate fraction or layer of the patch. For example, antifungal agents such as ciclopirox, chloroxylenol, triacetin, sulconazole, nystatin, undecylenic acid, tolnaftate, miconizole, clotrimazole, oxiconazole, griseofulvin, econazole, ketoconozole, and amphotericin B may be incorporated. Antibiotic agents such as mupirocin, erthromycin, clindamycin, gentamicin, polymyxin, bacitracin, silver sulfadiazine, and the like. Antiseptic agents such as iodine, Povidine-iodine, benzalkonium chloride, benzoic acid, chlorhexidine, nitrofurazone, benzoyl peroxide, hydrogen peroxide, hexachlorophene, phenol, resorcinol, and cetylpyridinium chloride likewise could be incorporated into the topical drug formulation or the patch. Furthermore, anti-inflammatories such as hydrocortisone, prednisone, triamci lo lone, betamethasone, dexamethasone, and the like may be incorporated. [0063]
  • In another embodiment, penetration enhancers can be included in the topical drug formulation or patch, to optimize local anesthetic delivery into and through the skin (Ghosh, T. K. et al. (1993), [0064] Pharm. Tech. 17(3):72-98; Ghosh, T. K. et al. (1993), Pharm. Tech. 17(4): 62-89; Ghosh, T. K. et al. (1993), Pharm. Tech. 17(5):68-76). The penetration enhancer should be pharmacologically inert, non-toxic, and non-allergenic, have rapid and reversible onset of action, and be compatible with the drug formulation (Pfister et al. Pharm. Tech. 14(9):132-140, incorporated herein by reference).
  • Useful penetration enhancers include but are not limited to ethyl alcohol, isopropyl alcohol, or octolyphenylpolyethylene glycol. More preferred penetration enhancers include oleic acid, polyethylene glycol 400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl myristate, methyl laurate, glycerol monooleate, and propylene glycol monooleate); and N-methyl pyrrolidone. [0065]
  • In yet another embodiment of the current invention, agents may be included to prolong the anesthetic effect, such as, a glucocorticosteroid (see, U.S. Pat. No. 5,922,340) or a vasoconstrictors, such as a catecolamine. [0066]
  • The present invention and its many attendant advantages will be understood from the foregoing description and it will be apparent that various changes in form, construction and arrangement of the parts thereof may be made without departing from the spirit and scope of the invention or sacrificing all of its material advantages, the form hereinbefore described are merely exemplary embodiments thereof. [0067]
  • EXAMPLE 1
  • Tension free mesh hernia repair was performed on approximately 300 male and female patients with groin hernias. An approximately three inch long incision was made and the hernia was repaired with layered and subcuticular closure with absorbable sutures (vicril sutures) followed by application of a 4 percent lidocaine reservoir patch (see U.S. Pat. No. 4,765,986, incorporated herein by reference). A fresh patch was applied about every six hours for the first 48 hours after surgery and supplemental oral analgesics (ibuprofen, Darvocet®, Toradol®, or Vicodin®) were administered at the patient's discretion. The patients were interviewed concerning pain relief and the quantity of oral analgesics the patient required. About 85% of the patients reported minimal pain and little need for oral analgesics. [0068]

Claims (25)

1. A method of preventing or ameliorating pain from a surgically closed wound in a subject comprising applying a pharmaceutically acceptable topical drug formulation comprising a therapeutically effective dose of a local anesthetic or a pharmaceutically acceptable salt thereof on or adjacent to an exterior surface of the wound.
2. The method of claim 1, wherein the wound resulted from a surgical procedure.
3. The method of claim 2, wherein the surgical procedure is selected from the group consisting of laparoscopy, hemiaplasty, breast biopsy, and excision of subcutaneous tumors.
4. The method of claim 2, wherein the surgical procedure is selected from the group consisting of hemiaplasty and laparoscopy.
5. The method of claim 1, wherein the local anesthetic is selected from the group consisting of lidocaine, tetracaine, bupivacaine, prilocaine, mepivacaine, procaine, chloroprocaine, ropivacaine, dibucaine, etidocaine, and benzocaine or a mixture thereof.
6. The method of claim 1, wherein the local anesthetic is lidocaine.
7. The method of claim 1, wherein the pharmaceutically acceptable topical drug formulation contains at least two local anesthetics.
8. The method of claim 7, wherein the local anesthetics are lidocaine and prilocaine.
9. The method of claim 7, wherein the local anesthetics are lidocaine and tetracaine.
10. The method of claim 1, wherein the phamnaceutically acceptable topical drug formulation does not comprise a penetration enhancer.
11. The method of claim 1, wherein the pharmaceutically acceptable topical drug formulation further comprises an agent effective to prolong the duration of a local anesthetic effect.
12. The method of claim 1, wherein the pharmaceutically acceptable topical drug formulation is covered with a dressing after the application step.
13. The method of claim 1, wherein the pharmaceutically acceptable topical drug formulation is contained in a patch.
14. The method of claim 13, wherein the patch is a type selected from the group consisting of monolithic drug-in-adhesive, multi-laminate drug-in-adhesive, matrix, and reservoir.
15. The method of claim 13, wherein the patch is a drug-in-adhesive type patch.
16. The method of claim 13, wherein the patch is a monolithic drug-in-adhesive type patch.
17. The method of claim 16, wherein the patch comprises a backing and an adhesive containing the anesthetic.
18. The method of claim 13, wherein the patch is a matrix type patch.
19. The method of claim 18, wherein the patch comprises an anesthetic containing matrix and an adhesive backing film overlay.
20. The method of claim 13, wherein the anesthetic comprises about 10 percent to about 30 percent of a weight of the patch.
21. The method of claim 13, wherein the anesthetic comprises about 15 percent to about 25 percent of a weight of the patch.
22. The method of claim 13, wherein the anesthetic comprises about 18 percent to about 22 percent of a weight of the patch.
23. The method of claim 13, wherein the patch is applied about every 18 hours to about every 48 hours after a surgical procedure.
24. The method of claim 13, wherein the patch is applied daily after a surgical procedure.
25. A patch comprising a local anesthetic in an amount therapeutically effective to prevent or ameliorate pain from a surgically closed wound in a mammal suffering from the pain packaged in association with instructions, the instructions comprising: applying the patch to the surgically closed wound.
US10/669,365 1999-10-25 2003-09-25 Local prevention or amelioration of pain from surgically closed wounds Abandoned US20040058994A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/425,925 US6383511B1 (en) 1999-10-25 1999-10-25 Local prevention or amelioration of pain from surgically closed wounds
US10/137,685 US6645521B2 (en) 1999-10-25 2002-05-03 Local prevention or amelioration of pain from surgically closed wounds
US10/669,365 US20040058994A1 (en) 1999-10-25 2003-09-25 Local prevention or amelioration of pain from surgically closed wounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/669,365 US20040058994A1 (en) 1999-10-25 2003-09-25 Local prevention or amelioration of pain from surgically closed wounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/137,685 Continuation US6645521B2 (en) 1999-10-25 2002-05-03 Local prevention or amelioration of pain from surgically closed wounds

Publications (1)

Publication Number Publication Date
US20040058994A1 true US20040058994A1 (en) 2004-03-25

Family

ID=23688594

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/425,925 Expired - Fee Related US6383511B1 (en) 1999-10-25 1999-10-25 Local prevention or amelioration of pain from surgically closed wounds
US10/137,685 Expired - Fee Related US6645521B2 (en) 1999-10-25 2002-05-03 Local prevention or amelioration of pain from surgically closed wounds
US10/669,365 Abandoned US20040058994A1 (en) 1999-10-25 2003-09-25 Local prevention or amelioration of pain from surgically closed wounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/425,925 Expired - Fee Related US6383511B1 (en) 1999-10-25 1999-10-25 Local prevention or amelioration of pain from surgically closed wounds
US10/137,685 Expired - Fee Related US6645521B2 (en) 1999-10-25 2002-05-03 Local prevention or amelioration of pain from surgically closed wounds

Country Status (11)

Country Link
US (3) US6383511B1 (en)
EP (1) EP1246590A4 (en)
JP (1) JP2003512401A (en)
CN (1) CN1413100A (en)
AU (1) AU779570B2 (en)
BR (1) BR0014996A (en)
CA (1) CA2387888C (en)
MX (1) MXPA02004106A (en)
NO (1) NO20021938L (en)
NZ (1) NZ518608A (en)
WO (1) WO2001030287A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029654A1 (en) * 2004-08-04 2006-02-09 Cassel R D Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain
US20100233271A1 (en) * 2007-11-07 2010-09-16 Sawan Samuel P Slow release of organic salts of local anesthetics for pain relief

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
EP1276475A2 (en) 2000-04-28 2003-01-22 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20050080043A1 (en) * 2000-09-20 2005-04-14 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6560483B1 (en) * 2000-10-18 2003-05-06 Minnesota High-Tech Resources, Llc Iontophoretic delivery patch
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US6620852B2 (en) * 2001-12-17 2003-09-16 Gerald Brogan Topical anesthetic
JP2006513224A (en) * 2002-12-20 2006-04-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティThe Board Of Trustees Of The Leland Stanford Junior University The combination of the ester local anesthetic
DE10315878B4 (en) * 2003-04-08 2009-06-04 Schwarz Pharma Ag A device for the transdermal administration of fesoterodine and using
ES2223277B1 (en) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Anesthetic composition for topical administration.
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
PT1814531E (en) 2004-10-21 2010-09-14 Durect Corp Transdermal delivery systems
WO2006096914A1 (en) 2005-03-15 2006-09-21 Animal Ethics Pty Ltd A topical analgesic composition
US20060211665A1 (en) * 2005-03-17 2006-09-21 Ranawat Chitranjan S Reduction of postoperative pain medication
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
WO2008008468A2 (en) * 2006-07-14 2008-01-17 Duncan Diane I Compositions and methods for fat reduction
CA2655809C (en) * 2006-07-21 2013-10-01 Bridge Pharma, Inc. Dermal anesthetic compounds
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
US7904146B2 (en) * 2006-11-13 2011-03-08 Travanti Pharma Inc. Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions
WO2008066775A2 (en) * 2006-11-22 2008-06-05 Duncan Diane I Compositions and methods to reduce fat and retract skin
ES2375417T3 (en) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International 1,4-diamino bicyclic analogs of retigabine as modulators of the potassium channels.
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR101583680B1 (en) * 2007-10-15 2016-01-08 알자 코퍼레이션 Once-a-day replacement transdermal administration of fentanyl
MX2011003510A (en) 2008-10-02 2011-06-17 Mylan Inc Method of making a multilayer adhesive laminate.
CN102281873A (en) * 2008-10-06 2011-12-14 迈兰技术有限公司 Amorphous rotigotine (Rotigotine) transdermal system
JP5669145B2 (en) 2009-07-02 2015-02-12 国立大学法人山口大学 Surface anesthetic
WO2011005853A2 (en) * 2009-07-08 2011-01-13 Msk Pharma, Llc Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome
DE102009056746A1 (en) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag A transdermal therapeutic system for the administration of peptides
US9925264B2 (en) 2011-05-10 2018-03-27 Itochu Chemical Frontier Corporation Non-aqueous patch
MX349572B (en) 2011-05-10 2017-08-03 Itochu Chemical Frontier Corp Non-aqueous patch.

Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419006A (en) * 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US3814095A (en) * 1972-03-24 1974-06-04 H Lubens Occlusively applied anesthetic patch
US3878175A (en) * 1973-07-27 1975-04-15 Plastik Devices Inc Highly absorbent spongy polymer materials
US4210670A (en) * 1977-07-06 1980-07-01 Astra Lakemedel Aktiebolag Antithrombotic agents
US4366243A (en) * 1981-04-17 1982-12-28 Miles Laboratories, Inc. Stabilization of glucose oxidase apoenzyme
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4646730A (en) * 1986-05-23 1987-03-03 Johnson & Johnson Products, Inc. Color stabilized hydrogel dressing and process
US4684558A (en) * 1986-06-30 1987-08-04 Nepera Inc. Adhesive polyethylene oxide hydrogel sheet and its production
US4699146A (en) * 1982-02-25 1987-10-13 Valleylab, Inc. Hydrophilic, elastomeric, pressure-sensitive adhesive
US4706680A (en) * 1986-06-30 1987-11-17 Nepera Inc. Conductive adhesive medical electrode assemblies
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4765986A (en) * 1985-06-20 1988-08-23 Liedtke Pharmed Gmbh Medicinal plaster for systemic use
US4777954A (en) * 1986-06-30 1988-10-18 Nepera Inc. Conductive adhesive medical electrode assemblies
US4989607A (en) * 1989-03-30 1991-02-05 Preston Keusch Highly conductive non-stringy adhesive hydrophilic gels and medical electrode assemblies manufactured therefrom
US5120544A (en) * 1989-06-19 1992-06-09 Henley International, Inc. Crosslinked hydrogel and method for making same
US5143071A (en) * 1989-03-30 1992-09-01 Nepera, Inc. Non-stringy adhesive hydrophilic gels
US5272139A (en) * 1986-08-27 1993-12-21 Cary George R Jr Amelioration or elimination of postoperative pain
US5330452A (en) * 1993-06-01 1994-07-19 Zook Gerald P Topical medicating device
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5405366A (en) * 1991-11-12 1995-04-11 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5415866A (en) * 1993-07-12 1995-05-16 Zook; Gerald P. Topical drug delivery system
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5667773A (en) * 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5744458A (en) * 1996-03-08 1998-04-28 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5760077A (en) * 1994-01-14 1998-06-02 Shahinian, Jr.; Lee Topical ophthalmic analgesic preparations for sustained and extended corneal analgesia
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5776952A (en) * 1995-07-17 1998-07-07 American Pharmed Labs, Inc. Method and composition for topical therapy of back pain and muscle tension
US5776611A (en) * 1996-11-18 1998-07-07 C.R. Bard, Inc. Crosslinked hydrogel coatings
US5798093A (en) * 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US5811078A (en) * 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5827529A (en) * 1991-03-30 1998-10-27 Teikoku Seiyaku Kabushiki Kaisha External preparation for application to the skin containing lidocaine
US5840755A (en) * 1995-07-17 1998-11-24 American Pharmed Labs, Inc. Method and composition for topical therapy of headaches
US5849762A (en) * 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US5863941A (en) * 1995-07-06 1999-01-26 Liedtke; Rainer K. Method and composition of a topical treatment of inner ear and labyrinth symptoms
US5888494A (en) * 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
US5916583A (en) * 1992-07-09 1999-06-29 Astra Aktiebolag Precipitation of one or more active compounds in situ
US5919479A (en) * 1995-07-28 1999-07-06 Zars, Inc. Noninvasive dermal anesthetics
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US6004964A (en) * 1997-07-14 1999-12-21 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulaitons and method of treating pruritus therewith
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6120792A (en) * 1998-04-29 2000-09-19 Juni; Jack E. Medicated skin patch and method for its use
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US20010006646A1 (en) * 1996-12-27 2001-07-05 Kathleen A Coyne Method and system for treatment of wounds
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6410048B1 (en) * 1997-11-13 2002-06-25 Laboratories Lavipharm S.A. Prolamin-plant polar lipid combination, preparation method and applications
US6425877B1 (en) * 1999-04-02 2002-07-30 Novasys Medical, Inc. Treatment of tissue in the digestive circulatory respiratory urinary and reproductive systems
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US6562644B2 (en) * 2000-08-08 2003-05-13 Matsushita Electric Industrial Co., Ltd. Semiconductor substrate, method of manufacturing the semiconductor substrate, semiconductor device and pattern forming method
US6743197B1 (en) * 1996-07-10 2004-06-01 Novasys Medical, Inc. Treatment of discrete tissues in respiratory, urinary, circulatory, reproductive and digestive systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
GR79380B (en) 1982-09-28 1984-10-22 Johnson & Johnson Prod Inc
JPH0443049B2 (en) * 1983-08-31 1992-07-15 Yamanouchi Pharma Co Ltd
US4769038A (en) * 1986-03-18 1988-09-06 C. R. Bard, Inc. Prostheses and techniques and repair of inguinal and femoral hernias
DE3862405D1 (en) * 1987-03-09 1991-05-23 Alza Corp Composition for the prevention of a contact allergy by simultaneously administering a corticosteroid to a sensiblisierenden drug.
EP0331392A3 (en) * 1988-03-01 1990-02-14 Alza Corporation Anesthesia and antisepsis of the skin
CA1338779C (en) * 1989-03-17 1996-12-10 Harry Hind Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
US5141515A (en) * 1990-10-11 1992-08-25 Eberbach Mark A Apparatus and methods for repairing hernias
US5122155A (en) * 1990-10-11 1992-06-16 Eberbach Mark A Hernia repair apparatus and method of use
US5232440A (en) * 1992-02-26 1993-08-03 Wilk Peter J Method and device for draining abscess
AU683022B2 (en) * 1992-09-10 1997-10-30 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
JP2897964B2 (en) * 1995-06-09 1999-05-31 ユーロ−セルティーク,エス.エイ. Formulations and methods for applying the local anesthetic in sustained
DE19546159A1 (en) * 1995-12-11 1997-06-12 Liedtke Pharmed Gmbh Method and composition of a topically effective therapy, post-operative and post traumatic wound pain
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1998039042A1 (en) * 1997-03-07 1998-09-11 Jackson Richard R Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5922026A (en) * 1997-05-01 1999-07-13 Origin Medsystems, Inc. Surgical method and prosthetic strip therefor
RU2234337C2 (en) 1997-09-26 2004-08-20 Ноувен Фамэсьютикэлз, Инк. Bioadhesive composition (variants), method for its preparing, device for delivery of active agent through mucosa, method for prolonged topical administration of one or more active agents to patient (variants) and method for reducing time required for sticking composition to mucosa tissue
US6299902B1 (en) * 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents

Patent Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419006A (en) * 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US3814095A (en) * 1972-03-24 1974-06-04 H Lubens Occlusively applied anesthetic patch
US3878175A (en) * 1973-07-27 1975-04-15 Plastik Devices Inc Highly absorbent spongy polymer materials
US4210670A (en) * 1977-07-06 1980-07-01 Astra Lakemedel Aktiebolag Antithrombotic agents
US4366243A (en) * 1981-04-17 1982-12-28 Miles Laboratories, Inc. Stabilization of glucose oxidase apoenzyme
US4699146A (en) * 1982-02-25 1987-10-13 Valleylab, Inc. Hydrophilic, elastomeric, pressure-sensitive adhesive
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4751087B1 (en) * 1985-04-19 1993-03-02 Riker Laboratories Inc
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4765986A (en) * 1985-06-20 1988-08-23 Liedtke Pharmed Gmbh Medicinal plaster for systemic use
US4646730A (en) * 1986-05-23 1987-03-03 Johnson & Johnson Products, Inc. Color stabilized hydrogel dressing and process
US4684558A (en) * 1986-06-30 1987-08-04 Nepera Inc. Adhesive polyethylene oxide hydrogel sheet and its production
US4777954A (en) * 1986-06-30 1988-10-18 Nepera Inc. Conductive adhesive medical electrode assemblies
US4706680A (en) * 1986-06-30 1987-11-17 Nepera Inc. Conductive adhesive medical electrode assemblies
US5272139A (en) * 1986-08-27 1993-12-21 Cary George R Jr Amelioration or elimination of postoperative pain
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
USRE37727E1 (en) * 1989-03-17 2002-06-04 Hind Health Care Method for treating nerve injury pain associated with shingles
US5143071A (en) * 1989-03-30 1992-09-01 Nepera, Inc. Non-stringy adhesive hydrophilic gels
US5354790A (en) * 1989-03-30 1994-10-11 Nepera, Inc. Methods for the preparation of non-stringy adhesive hydrophilic gels
US4989607A (en) * 1989-03-30 1991-02-05 Preston Keusch Highly conductive non-stringy adhesive hydrophilic gels and medical electrode assemblies manufactured therefrom
US5120544A (en) * 1989-06-19 1992-06-09 Henley International, Inc. Crosslinked hydrogel and method for making same
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5827529A (en) * 1991-03-30 1998-10-27 Teikoku Seiyaku Kabushiki Kaisha External preparation for application to the skin containing lidocaine
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US5405366A (en) * 1991-11-12 1995-04-11 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same
US5916583A (en) * 1992-07-09 1999-06-29 Astra Aktiebolag Precipitation of one or more active compounds in situ
US6238702B1 (en) * 1992-09-10 2001-05-29 Children's Medical Center Corp. High load formulations and methods for providing prolonged local anesthesia
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5330452A (en) * 1993-06-01 1994-07-19 Zook Gerald P Topical medicating device
US5415866A (en) * 1993-07-12 1995-05-16 Zook; Gerald P. Topical drug delivery system
US5810786A (en) * 1993-09-24 1998-09-22 Richard R. Jackson Tissue-numbing anesthetic articles
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
US5760077A (en) * 1994-01-14 1998-06-02 Shahinian, Jr.; Lee Topical ophthalmic analgesic preparations for sustained and extended corneal analgesia
US5741510A (en) * 1994-03-30 1998-04-21 Lectec Corporation Adhesive patch for applying analgesic medication to the skin
US6361790B1 (en) * 1994-03-30 2002-03-26 Lectec Corporation Method of forming adhesive patch for applying medication to the skin
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US6096333A (en) * 1994-03-30 2000-08-01 Lectec Corporation Method of forming adhesive patch for applying medication to the skin
US6096334A (en) * 1994-03-30 2000-08-01 Lectec Corporation Adhesive patch for applying medication to the skin and method
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5863941A (en) * 1995-07-06 1999-01-26 Liedtke; Rainer K. Method and composition of a topical treatment of inner ear and labyrinth symptoms
US5776952A (en) * 1995-07-17 1998-07-07 American Pharmed Labs, Inc. Method and composition for topical therapy of back pain and muscle tension
US5840755A (en) * 1995-07-17 1998-11-24 American Pharmed Labs, Inc. Method and composition for topical therapy of headaches
US5919479A (en) * 1995-07-28 1999-07-06 Zars, Inc. Noninvasive dermal anesthetics
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5744458A (en) * 1996-03-08 1998-04-28 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5981513A (en) * 1996-03-08 1999-11-09 Adolor Corporation Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5888494A (en) * 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
US5667773A (en) * 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US6743197B1 (en) * 1996-07-10 2004-06-01 Novasys Medical, Inc. Treatment of discrete tissues in respiratory, urinary, circulatory, reproductive and digestive systems
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5776611A (en) * 1996-11-18 1998-07-07 C.R. Bard, Inc. Crosslinked hydrogel coatings
US20010006646A1 (en) * 1996-12-27 2001-07-05 Kathleen A Coyne Method and system for treatment of wounds
US5798093A (en) * 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5811078A (en) * 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5869521A (en) * 1997-07-14 1999-02-09 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5849762A (en) * 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US6004964A (en) * 1997-07-14 1999-12-21 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulaitons and method of treating pruritus therewith
US6410048B1 (en) * 1997-11-13 2002-06-25 Laboratories Lavipharm S.A. Prolamin-plant polar lipid combination, preparation method and applications
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US6120792A (en) * 1998-04-29 2000-09-19 Juni; Jack E. Medicated skin patch and method for its use
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6425877B1 (en) * 1999-04-02 2002-07-30 Novasys Medical, Inc. Treatment of tissue in the digestive circulatory respiratory urinary and reproductive systems
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6645521B2 (en) * 1999-10-25 2003-11-11 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6562644B2 (en) * 2000-08-08 2003-05-13 Matsushita Electric Industrial Co., Ltd. Semiconductor substrate, method of manufacturing the semiconductor substrate, semiconductor device and pattern forming method

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029654A1 (en) * 2004-08-04 2006-02-09 Cassel R D Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain
US20100233271A1 (en) * 2007-11-07 2010-09-16 Sawan Samuel P Slow release of organic salts of local anesthetics for pain relief
US8920843B2 (en) 2007-11-07 2014-12-30 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
USRE46397E1 (en) 2007-11-07 2017-05-09 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief

Also Published As

Publication number Publication date
NO20021938D0 (en) 2002-04-24
AU779570B2 (en) 2005-01-27
US6645521B2 (en) 2003-11-11
NO20021938L (en) 2002-05-28
CN1413100A (en) 2003-04-23
US6383511B1 (en) 2002-05-07
BR0014996A (en) 2002-06-18
JP2003512401A (en) 2003-04-02
NZ518608A (en) 2008-01-31
EP1246590A1 (en) 2002-10-09
CA2387888A1 (en) 2001-05-03
AU1211801A (en) 2001-05-08
MXPA02004106A (en) 2003-08-20
WO2001030287A1 (en) 2001-05-03
CA2387888C (en) 2009-04-07
EP1246590A4 (en) 2004-07-07
US20020128285A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US6495158B1 (en) Acne patch
CN1131018C (en) Drug-containing adhesive composite transdermal administration plaster and preparation method thereof
US5505956A (en) Medicinal adhesive for percutaneous administration
US6416749B1 (en) Treatment for onychomycosis topically applying salicylic acid, optionally in combination with a retinoid
US4690683A (en) Transdermal varapamil delivery device
CA1089362A (en) Therapeutic system for administering clonidine transdermally and process for making same
US4704119A (en) Method comprising transdermal and buccal treatment of angina
Kerr et al. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients
CA2424579C (en) Ultraviolet-screening patch
RU2233156C2 (en) Composition for topical application of methylfenidate (variants) and method for treatment of attention deficiency disorder and disorder of type attention deficiency/hyperactivity (variants)
JP2701951B2 (en) Printed skin permeability drug administration device
US5202125A (en) Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
ES2276697T3 (en) Formulation capable of changing phase to deliver drugs topically.
US5993836A (en) Topical anesthetic formulation
US8178115B2 (en) Method and composition for the treatment of scars
EP1316308B1 (en) Transdermal therapeutic patch with capsaicin and capsaicin analogs
JP4346696B2 (en) Transdermal therapeutic system
US4725609A (en) Method of promoting healing
EP0767659B1 (en) Transdermal administration of oxybutynin
US5091186A (en) Biphasic transdermal drug delivery device
US5662925A (en) Transdermal delivery system with adhesive overlay and peel seal disc
US4031894A (en) Bandage for transdermally administering scopolamine to prevent nausea
US6613350B1 (en) Electrical apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds
US6756053B2 (en) Controlled heat induced rapid delivery of pharmaceuticals from skin depot
US4661105A (en) Medical bandage for administering vasodilator drug

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION